Comparison · NCT00757822-sae
Dronabinol- Experimental Therapy vs Ondansetron-control Therapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dronabinol- Experimental Therapy vs Ondansetron-control Therapy: serious adverse events. Trial comparisons, record NCT00757822-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00757822-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.141 | 0.0845 | 0.227 | wilson | |
| Risk in group 2 | 0.114 | 0.0629 | 0.197 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0277 | -0.073 | 0.127 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.24 | 0.575 | 2.69 | log | |
| Odds ratio, group 1 over group 2 | 1.28 | 0.531 | 3.1 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Dronabinol- Experimental Therapy than on Ondansetron-control Therapy | 36.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dronabinol- Experimental Therapy | Dronabinol (5mg) was administered po 30-60 min prior to start of elective abdominal surgery scheduled for same day discharge to home. | 13 | 92 | EG000 |
| Group 2 | Ondansetron-control Therapy | Ondansetron (4 mg) was administered iv 20-30 min prior to end of elective abdominal surgery scheduled for same day discharge to home. | 10 | 88 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1-72 days post-surgery (e.g. 30 days post last follow-up visit at 2-6 weeks)
Source ClinicalTrials.gov
Trial
- Title
- Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients
- NCT number
- NCT00757822
- Phases
- NA
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Dronabinol, Ondansetron
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2016-05-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00757822?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00757822-sae